Are UNF, NSA, CYCN, ULYX Obtaining Fair Deals for their Shareholders?
PRNewswire (Thu, 9-Apr 3:30 PM ET)
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--CYCN, CECO, THR, and CWAN
PRNewswire (Wed, 8-Apr 2:15 PM ET)
Globe Newswire (Tue, 7-Apr 12:50 PM ET)
Globe Newswire (Fri, 3-Apr 7:14 AM ET)
PRNewswire (Thu, 2-Apr 2:45 PM ET)
Business Wire (Thu, 2-Apr 1:08 AM ET)
PRNewswire (Wed, 1-Apr 4:53 PM ET)
Market Chameleon (Wed, 1-Apr 3:54 AM ET)
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
Business Wire (Wed, 1-Apr 7:05 AM ET)
Globe Newswire (Tue, 17-Feb 7:00 AM ET)
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. The company focuses on enabling the full therapeutic potential of next-generation sGC stimulators and neuropsychiatric diseases. Its pipeline products include Olinciguat, Praliciguat, and others.
Cyclerion Therapeutics trades on the NASDAQ stock market under the symbol CYCN.
As of April 30, 2026, CYCN stock price declined to $3.26 with 23,669 million shares trading.
CYCN has a beta of 1.32, meaning it tends to be more sensitive to market movements. CYCN has a correlation of 0.01 to the broad based SPY ETF.
CYCN has a market cap of $12.41 million. This is considered a Sub-Micro Cap stock.
Last quarter Cyclerion Therapeutics reported $1 million in Revenue and -$.19 earnings per share. This beat revenue expectation by $925,000 and exceeded earnings estimates by $.19.
In the last 3 years, CYCN traded as high as $9.47 and as low as $1.03.
The top ETF exchange traded funds that CYCN belongs to (by Net Assets): ONEQ, VXF.
CYCN has underperformed the market in the last year with a return of -2.7%, while SPY returned +30.1%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in CYCN shares. However, CYCN has outperformed the market in the last 3 month and 2 week periods, returning +138.0% and +7.6%, while SPY returned +3.1% and +2.0%, respectively. This indicates CYCN has been having a stronger performance recently.
CYCN support price is $2.99 and resistance is $3.65 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CYCN shares will trade within this expected range on the day.
